H.C. Wainwright initiated coverage of CervoMed (CRVO) with a Buy rating and $42 price target The company’s lead asset neflamapimod is currently in Phase 2b development for dementia with Lewy bodies, the analyst tells investors in a research note. The firm says CervoMed is combating an area of significant unmet need in neurology with a mechanistically and clinically differentiated lead candidate.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVO:
Questions or Comments about the article? Write to editor@tipranks.com